Example: Heart Attack

Search clinical trials for: Trastuzumab

Total 1007 results

NCT04439110

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma
NCT04429633

Recruiting

Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Conditions: Cardiotoxicity; Breast Cancer; Prevention; Adjuvant; Trastuzumab
NCT04430738

Not yet recruiting

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers

Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; Esophageal and GEJ Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma
NCT04425018

Not yet recruiting

MARGetuximab Or Trastuzumab (MARGOT)

Conditions: Breast Cancer; Stage II Breast Cancer; Stage III Breast Cancer; HER2-positive Breast Cancer
NCT04420598

Active, not recruiting

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Conditions: Advanced Breast Cancer; HER2-positive Breast Cancer; Brain Metastases; Leptomeningeal Metastasis
NCT04419181

Not yet recruiting

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Conditions: HER2-positive Breast Cancer
NCT04398914

Not yet recruiting

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Conditions: Breast Cancer Invasive
NCT04400695

Not yet recruiting

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Conditions: Breast Cancer
NCT04395508

Available

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Conditions: HER2-positive Breast Cancer
NCT04385563

Recruiting

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Conditions: HER2-positive Metastatic Breast Cancer
NCT04383275

Not yet recruiting

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Conditions: Breast Cancer
NCT04382352

Recruiting

B002 in Patients With HER2-positive Breast Cancer

Conditions: Recurrent Breast Cancer; Metastatic Breast Cancer
NCT04380012

Recruiting

A Clinical Study of Pyrotinib in Patients of Advanced Colorectal Cancer With Her2 Variation

Conditions: Colorectal Cancer
NCT04379596

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)

Conditions: Gastric Cancer
NCT04367090

Not yet recruiting

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04351230

Not yet recruiting

Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer

Conditions: Anatomic Stage IV Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8
NCT04341181

Not yet recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Conditions: Cancer; Tumors; Neoplasms; Neoplasia
NCT04337658

Not yet recruiting

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Conditions: HER2-positive Breast Cancer
NCT04334330

Not yet recruiting

Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Conditions: Breast Cancer; Brain Metastases
NCT04335409

Not yet recruiting

Pneumonitis After Radiotherapy of Breast or Lung Cancer

Conditions: Breast Cancer; Lung Cancer
NCT04329065

Not yet recruiting

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
NCT04329429

Recruiting

A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer.

Conditions: Biliary Tract Cancer
NCT04309578

Recruiting

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Conditions: Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
NCT04307329

Not yet recruiting

Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial

Conditions: Breast Cancer
NCT04301375

Not yet recruiting

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Conditions: Mammary Cancer
NCT04302441

Recruiting

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

Conditions: Breast Cancer
NCT04298918

Not yet recruiting

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Conditions: Breast Cancer
NCT04296162

Recruiting

Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)

Conditions: Breast Cancer
NCT04296942

Not yet recruiting

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Conditions: Breast Cancer; Triple Negative Breast Cancer; HER2+ Breast Cancer; Hormone Receptor Negative Breast Cancer; Metastatic Breast Cancer
NCT04294628

Not yet recruiting

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Conditions: Metastatic Malignant Neoplasm; Refractory Malignant Neoplasm; Unresectable Malignant Neoplasm
NCT04293796

Recruiting

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)

Conditions: Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
NCT04290793

Not yet recruiting

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Conditions: Breast Cancer
NCT04288141

Recruiting

A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies

Conditions: HER2-positive Breast Cancer
NCT04285671

Not yet recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Conditions: Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
NCT04281576

Recruiting

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Conditions: Gastric Cancer; GastroEsophageal Cancer
NCT04281641

Recruiting

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

Conditions: HER2-positive Breast Cancer
NCT04280341

Not yet recruiting

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

Conditions: HER2-Positive Solid Tumors
NCT04278144

Recruiting

A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

Conditions: Neoplasm, Metastatic; Neoplasm, Breast; Neoplasm, Gastric
NCT04276337

Active, not recruiting

Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy

Conditions: HER2-positive Breast Cancer; Chemotherapy Effect; Circulating Tumor DNA
NCT04266249

Recruiting

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8
NCT04262804

Recruiting

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Conditions: Breast Cancer Metastatic
NCT04253561

Recruiting

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Conditions: Metastatic Breast Cancer
NCT04254263

Not yet recruiting

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

Conditions: Locally Advanced Breast Cancer
NCT04255056

Not yet recruiting

Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab

Conditions: Breast Cancer
NCT04249440

Completed

Systemic Treatment Preoperatively vs Postoperatively in HER2 Positive Early Breast Cancer

Conditions: Breast Cancer; HER2; Preoperative Systemic Treatment
NCT04246502

Not yet recruiting

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Conditions: Metastatic Breast Cancer
NCT04246671

Not yet recruiting

Phase 1/2 Trial of Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

Conditions: Breast Cancer; Gastric Cancer; Cancer
NCT04236310

Not yet recruiting

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Conditions: Breast Cancer; HER2-positive Breast Cancer; ER-positive Breast Cancer
NCT04235101

Recruiting

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

Conditions: Solid Tumor
NCT04220203

Approved for marketing

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Conditions: HER2-positive Breast Cancer

Search clinical trials for: Trastuzumab

Recent CRA jobs

Business Intelligence Analyst

Clinical Project Manager / Senior Clinical Project Manager (home-based) -- Early Clinical Development

Clin Data Prgmg Assoc 1

BI Architect

Business Intelligence/DWH Architect

Internship in Clinical Research (m/w/d) – office based in Basel – 6-month contract

Clin Data Coord 2

Assoc Clin Data Coder

Medisch afgevaardigde natuurlijke producten Gent + Waasland

Medical Laboratory Assistant